Invasive fungal disease in a large cohort of hospitalized children with inborn errors of immunity in China
- PMID: 40205718
- DOI: 10.1111/pai.70074
Invasive fungal disease in a large cohort of hospitalized children with inborn errors of immunity in China
Abstract
Background: Invasive fungal disease (IFD) is a common complication observed in inborn errors of immunodeficiency (IEI) patients, and little is known about the overall prevalence of IFD in IEI patients. We aimed to summarize the fungal spectrum and outcomes of IFDs in a Chinese cohort of hospitalized patients with IEI.
Methods: In this retrospective study, 607 IEI patients hospitalized from January 2018 to June 2022 were included. Demographic, clinical, and fungal infection data and IEI patient characteristics were collected and analyzed according to the IEI classification.
Results: One hundred and two IEI patients were diagnosed with proven or probable IFD. The overall prevalence of IFD was 17% (102/607). There were 29 different genotypes, among which CYBB (25%), CD40LG (9%), and RAG1 (7%) mutations were the most common. Most IFD infections (87/102) were caused by one fungus. Invasive Aspergillus, Pneumocystis jirovecii pneumonia, and Penicillium infections were more commonly observed in patients with congenital defects in phagocytes, immunodeficiencies affecting cellular and humoral immunity, and defects in innate immunity, respectively. Most IFDs observed in IEI patients were single-site infections, most of which were lung infections (74%). Seventeen patients were diagnosed with disseminated IFDs, nine of which were caused by Penicillium. All patients received antifungal treatments. Eight patients (8%) died within 3 months of IFD diagnosis.
Conclusions: IFD occurrence suggests the presence of immunity impairment. The IFD fungal profile may indicate different types of IEI. Early recognition of immunodeficiency and optimal timing of antifungal therapy can reduce fatality in IEI patients.
Keywords: SCID; fungal spectrum; inborn errors of immunity; invasive fungal disease; metagenomic next‐generation sequencing.
© 2025 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Similar articles
-
The Spectrum of Inborn Errors of Immunity in the United Arab Emirates: 5 Year Experience in a Tertiary Center.Front Immunol. 2022 Jan 31;13:837243. doi: 10.3389/fimmu.2022.837243. eCollection 2022. Front Immunol. 2022. PMID: 35173743 Free PMC article.
-
Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China.Tumour Biol. 2016 Jun;37(6):7893-900. doi: 10.1007/s13277-015-4441-8. Epub 2015 Dec 23. Tumour Biol. 2016. PMID: 26700667
-
Clinical features in proven and probable invasive fungal disease in children and adolescents at a pediatric referral center: a 5-year experience.World J Pediatr. 2019 Jun;15(3):270-275. doi: 10.1007/s12519-019-00259-x. Epub 2019 Apr 22. World J Pediatr. 2019. PMID: 31011987
-
Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity.Front Cell Infect Microbiol. 2022 Sep 8;12:987692. doi: 10.3389/fcimb.2022.987692. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36159645 Free PMC article.
-
Primary immunodeficiencies underlying fungal infections.Curr Opin Pediatr. 2013 Dec;25(6):736-47. doi: 10.1097/MOP.0000000000000031. Curr Opin Pediatr. 2013. PMID: 24240293 Free PMC article. Review.
Cited by
-
Characterizing neonatal community-acquired invasive fungal infections: Clinical profiles, pathogens, and underlying conditions.Medicine (Baltimore). 2025 Jun 20;104(25):e42921. doi: 10.1097/MD.0000000000042921. Medicine (Baltimore). 2025. PMID: 40550072 Free PMC article.
References
REFERENCES
-
- Jenks JD, Cornely OA, Chen SC, Thompson GR, Hoenigl M. Breakthrough invasive fungal infections: who is at risk? Mycoses. 2020;63:1021‐1032.
-
- Cifaldi C, Ursu GM, D'Alba I, et al. Main human inborn errors of immunity leading to fungal infections. Clin Microbiol Infect. 2022;28:1435‐1440.
-
- Lionakis MS. Primary immunodeficiencies and invasive fungal infection: when to suspect and how to diagnose and manage. Curr Opin Infect Dis. 2019;32:531‐537.
-
- Lionakis MS, Iliev ID, Hohl TM. Immunity against fungi. JCI Insight. 2017;2(11):e93156. doi:10.1172/jci.insight.93156
-
- Lionakis MS, Levitz SM. Host control of fungal infections: lessons from basic studies and human cohorts. Annu Rev Immunol. 2018;36:157‐191.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous